EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE (Atripla) Nursing Considerations

What is the generic name?

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

What is the Trade Name for EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE?

Atripla

What are the Indications for EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE?

• 1 INDICATIONS AND USAGE ATRIPLA ¬Æ is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. ATRIPLA is a three-drug combination of efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. ( 1 )

References: https://open.fda.gov/